Analyst Expectations for Intra-Cellular Therapies's Future
Portfolio Pulse from Benzinga Insights
In the past 3 months, 14 analysts have published their opinions on Intra-Cellular Therapies (NASDAQ:ITCI) stock, with an average 12-month price target of $76.29. The average price target has increased by 3.88% over the past month.
June 22, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
14 analysts have published opinions on Intra-Cellular Therapies (NASDAQ:ITCI) stock in the past 3 months, with an average 12-month price target of $76.29, up 3.88% over the past month.
The average 12-month price target for Intra-Cellular Therapies has increased by 3.88% over the past month, indicating a positive sentiment among analysts. This could lead to a short-term increase in the stock price as investors may take these analyst opinions into account.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100